Clinical trials: Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial studies the side effects and how well EGEN-001 works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that is persistent or has come back.
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT01118052
- Testing
- Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have refractory…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00053833
- Testing
- irinotecan
- Where
- 100 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Neoplasm, Fallopian Tube Neoplasms
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05257408
- Testing
- Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- Corcept Therapeutics
Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.
- Conditions
- Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- AICE (NCT01669226)
- Testing
- PEip (weekly) and TCiv, TCiv
- Where
- 7 sites in China
- Volunteers
- 215 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
The receptor tyrosine kinase AXL is a pathway that plays a crucial role in metastasis and chemoresistance. Overexpression of AXL has been associated with metastasis, recurrence, and chemoresistance in various cancer including…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03607955
- Testing
- AVB-S6-500, Paclitaxel, Carboplatin
- Sponsor
- Washington University School of Medicine
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014
- Trial name
- NCT02713386
- Testing
- Carboplatin, Paclitaxel, Ruxolitinib Phosphate
- Where
- 110 sites in United States
- Volunteers
- 147 people
- Sponsor
- NRG Oncology
Ovarian Cancer, Ovarian Carcinoma
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Stage II Ovary Cancer, Stage II Ovarian Cancer
- Trial name
- NCT05429970
- Testing
- Mind-body resilience training, Music therapy, Propranolol
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
In April 2017, Tesaro, Inc. opened an expanded access program (EAP) to make niraparib, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor, available to eligible women with recurrent epithelial ovarian, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04546373
- Testing
- Niraparib
- Where
- 57 sites in Spain
- Volunteers
- 316 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Ovarian Cancer
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after…
- Trial name
- NCT02132988
- Testing
- OPT-822/OPT-821
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Mackay Memorial Hospital
Ovarian Cancer
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
- Trial name
- NCT00866697
- Testing
- Pazopanib
- Where
- 318 sites in United States, Australia and 15 more
- Volunteers
- 940 people
- Sponsor
- Novartis Pharmaceuticals
Fallopian Tube Cancer, Ovarian Cancer
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003380
- Testing
- etoposide, pegylated liposomal doxorubicin hydrochloride
- Where
- 63 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Ovarian Carcinoma
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer
- Trial name
- NCT03748186
- Testing
- STRO-002
- Where
- 27 sites in United States, Spain
- Volunteers
- 136 people
- Sponsor
- Sutro Biopharma, Inc.
Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II
Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy
The purpose of this research study is to see if it is feasible to receive heated chemotherapy or heated intraperitoneal chemotherapy (HIPEC) inserted directly into the abdomen at the time of a Second Look Reassessment Surgery and…
- Conditions
- Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III, Stage I Fallopian Tube Cancer
- Trial name
- HIPEC (NCT04415944)
- Testing
- Second look laparoscopy reassessment surgery (SLLRS), HIPEC with Carboplatin, FACT-O Quality of Life Questionnaire
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Epithelial Ovarian Cancer, Fallopian Tube Neoplasms
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- SUROVA (NCT06223763)
- Testing
- Cytoreductive surgery, Neoadjuvant chemotherapy, Adjuvant chemotherapy
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT00262990
- Testing
- EPO906 (Patupilone), doxorubicin
- Where
- 149 sites in United States, Australia and 10 more
- Volunteers
- 829 people
- Sponsor
- Novartis Pharmaceuticals
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00003944
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Female Reproductive Cancer
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advanced ovarian epithelial, primary…
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00182767
- Testing
- ixabepilone, pegylated liposomal doxorubicin hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)